Education
About Us
Working with TipRanks
Follow Us
Eterna Therapeutics Inc. (ERNA)
:ERNA
Total Valuation
Eterna Therapeutics has a market cap or net worth of $14.22M. The enterprise value is ―.
Market Cap$14.22M
Enterprise Value―
Share Statistics
Eterna Therapeutics has 62,363,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,363,760
Owned by Insiders32.72%
Owned by Institutions0.76%
Financial Efficiency
Eterna Therapeutics’s return on equity (ROE) is -26.18 and return on invested capital (ROIC) is -617.99%.
Return on Equity (ROE)-26.18
Return on Assets (ROA)-8.45
Return on Invested Capital (ROIC)-617.99%
Return on Capital Employed (ROCE)-6.72
Revenue Per Employee97.00K
Profits Per Employee-7.42M
Employee Count6
Asset Turnover0.11
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eterna Therapeutics is -0.09. Eterna Therapeutics’s PEG ratio is >-0.01.
PE Ratio-0.09
PS Ratio0.00
PB Ratio1.40
Price to Fair Value2.36
Price to FCF-0.56
Price to Operating Cash Flow-0.15
PEG Ratio>-0.01
Income Statement
In the last 12 months, Eterna Therapeutics had revenue of 582.00K and earned -44.54M in profits. Earnings per share was -3.26.
Revenue582.00K
Gross Profit486.00K
Operating Income-15.67M
Pretax Income-44.51M
Net Income-44.54M
EBITDA-36.12M
Earnings Per Share (EPS)-3.26
Cash Flow
In the last 12 months, operating cash flow was -15.84M and capital expenditures -369.00K, giving a free cash flow of -16.20M billion.
Operating Cash Flow-15.84M
Free Cash Flow-16.20M
Free Cash Flow per Share-0.26
Dividends & Yields
Eterna Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change-87.96%
50-Day Moving Average0.21
200-Day Moving Average0.67
Relative Strength Index (RSI)54.81
Average Volume (3m)169.21K
Important Dates
Eterna Therapeutics upcoming earnings date is Apr 14, 2023, TBA Not Confirmed.
Last Earnings DateNov 8, 2022
Next Earnings DateApr 14, 2023
Ex-Dividend Date―
Financial Position
Eterna Therapeutics as a current ratio of 0.80, with Debt / Equity ratio of 40.21%
Current Ratio0.80
Quick Ratio0.80
Debt to Market Cap0.17
Net Debt to EBITDA0.03
Interest Coverage Ratio-2.32
Taxes
In the past 12 months, Eterna Therapeutics has paid 30.00K in taxes.
Income Tax30.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Eterna Therapeutics EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.18.
EV to Sales5.10
EV to EBITDA-0.08
EV to Free Cash Flow-0.18
EV to Operating Cash Flow-0.19
Balance Sheet
Eterna Therapeutics has $1.73M in cash and marketable securities with $684.00K in debt, giving a net cash position of -$1.04M billion.
Cash & Marketable Securities$1.73M
Total Debt$684.00K
Net Cash-$1.04M
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.03
Margins
Gross margin is -9.45%, with operating margin of -2693.13%, and net profit margin of -7652.75%.
Gross Margin-9.45%
Operating Margin-2693.13%
Pretax Margin-7647.59%
Net Profit Margin-7652.75%
EBITDA Margin-6206.01%
EBIT Margin-6487.46%
Analyst Forecast
The average price target for Eterna Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―